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Abstract Age-related macular degeneration (AMD)
is one of the leading causes of blindness in the devel-
oped world. Although effective treatment modalities
such as anti-VEGF treatment have been developed
for neovascular AMD, there is still no effective
treatment for geographical atrophy, and therefore the
most cost-effective management of AMD is to start
with prevention. This review looks at current evi-
dence on preventive measures targeted at AMD.
Modalities reviewed include (1) nutritional supple-
ments such as the Age-Related Eye Disease Study
(AREDS) formula, lutein and zeaxanthin, omega-3
fatty acid, and berry extracts, (2) lifestyle modiﬁca-
tions, including smoking and body-mass-index, and
(3) ﬁltering sunlight, i.e. sunglasses and blue-block-
ing intraocular lenses. In summary, the only proven
effective preventive measures are stopping smoking
and the AREDS formula.
Keywords AREDS  Age-related macular
degeneration  AMD  Vitamin E  Beta-carotene 
Neovascular AMD  Yellow IOL  Sunlight ﬁltration 
Prevention
Introduction
Age-related macular degeneration (AMD) is one of
the leading causes of blindness in developed coun-
tries [1–3]; currently 11.5% of the population in the
United States is affected [1]. The exact pathogenesis
of AMD remains unknown [4], but one of the main
components is thought to be oxidative stress [5, 6]:
the retina, because of its high oxygen concentration
and intense light exposure, is susceptible to damage
by oxidative stress [6]. Early stages of AMD can be
asymptomatic but can cause severe impairment of
central vision in late stages. Details of the most up-to-
date classiﬁcation of AMD are given in Table 1.
There have been some promising new treatments in
recent years since the emergence of anti-vascular
endothelial growth factor (anti-VEGF) agents, and
numerous pivotal studies have proven their effective-
ness in controlling neovascular AMD [7]. However,
at the moment, costs for these drugs are high and
patients may have to undergo multiple injections.
Taking in consideration the ever-growing popula-
tion, the incidence of AMD will only increase. In the
UnitedStatesalone,itisthoughtthattheincidencemay
doubleinthenext20years[1],andsowilltheresources
and effort spent in the area. Even if anti-VEGF agents
are made cheaper and more available, more and more
patients will have to rely on them, and as a result the
burden on the healthcare system will be increased [8].
It may be more economical to tackle AMD with
prevention. Studies done on AMD prevention usually
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DOI 10.1007/s10792-010-9397-5fallintooneofthreeareas:(1)nutritionalsupplements,
(2) lifestyle modiﬁcations, (3) ﬁltering sunlight. It is
vitalthatophthalmologistsandgeneralpractitionersbe
aware ofthe latestandupdatedevidence.Inthisarticle
we hope to provide an overview of current opinions on
the prevention of AMD.
Methods
An evidence-based approach was adopted in the
review process. The literature up to December 2009
was searched for keywords ‘age-related macular
degeneration’, ‘macular’, ‘AMD’, ‘antioxidants’,
‘mineral supplements’, ‘dietary supplements’, and
‘prevention’. We used the databases Medline, The
Cochrane Library, Embase.com, Web of Knowledge,
and Google Scholar. The search was limited to
studies in human subjects, in English. Strength of
evidence and rating of recommendation were
assessed according to the method described previ-
ously [9], and are summarized in Table 3.
Evidence synthesis
Nutritional supplements
Most studies focused on four types of supplements:
1. AREDS or AREDS-like formulas,
2. Lutein and zeaxanthin,
3. Omega-3 fatty acids,
4. Berry extracts.
AREDS or AREDS-like formulas
The Age-Related Eye Disease Study (AREDS) was
designed to investigate whether active treatment with
supplements such as vitamins and minerals can
reduce the risk of advanced AMD. The main
components of the formula were vitamin A (as
beta-carotene), vitamin C, vitamin E, and zinc. These
ingredients were thought to exert a protective effect
on retinal cells by counteracting oxidative stresses
[10–15]. The formula was a type of active treatment
and therefore the dosages of ingredients were much
higher than the Dietary Reference Intake (DRI),
which is a system of nutrition recommendations from
the Institute of Medicine of the USA National
Academy [16]. For instance, the amount of vitamin
C included in the AREDS formula was 500 mg per
day, whereas the DRI for an adult is only 90 mg per
day (a medium-sized orange contains around 70 mg
of vitamin C, and therefore one has to eat almost
seven or eight oranges to obtain 500 mg of vitamin
C). A detailed comparison of nutrient contents
between the AREDS formula and common fruits is
given in Table 2.
Subjects were categorized initially according to
the suggested grading system [17], and then were
asked to take either the supplements or placebo on
twice a day. The progress of 3,640 subjects was
Table 1 Categorization of age-related macular degeneration (AMD) according to the Age-Related Eye Disease Study (AREDS)
guidelines
Brief description Clinical features Visual acuity
Category 1 Free of AMD in both eyes \5 small drusen in one or both eyes 20/32 or better in both eyes
Category 2 Mild to borderline AMD
in one or both eyes
Multiple small or intermediate drusen in one
or both eyes
Pigment abnormalities in one or both eyes
20/32 or better in both eyes
Category 3 Absence of advanced AMD
in both eyes
Intermediate or large drusen
Geographical atrophy
Features not involving central macular
20/32 or better in better eye
Category 4 Advanced AMD in one eye Advanced AMD or geographical atrophy
in worse eye
No such features in better eye
20/32 or better in better eye
Key: Small drusen,\63 lm in diameter (disc diameter around 1500 lm); intermediate drusen, 63–124 lm in diameter; large drusen,
[125 lm in diameter; pigment abnormalities refer to either hyperpigmentation or depigmentation
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123monitored for an average of 6.3 years. In essence, the
results showed a 25% reduction in risk of progression
to advanced AMD if recommended doses of antiox-
idants and zinc were taken daily. However, this was
seen in category 3 or 4 patients only, probably
because of the higher natural risk of progression to
advanced AMD. Results were not signiﬁcant for
category 2 or 1, i.e. those with small drusen only (the
5-year risk of progression to advanced AMD in
category 2 was only 1.3% and in category 1\1%).
However, in the USA 80% of people over age 70
fall into category 1 or 2, and hence most people
would probably not beneﬁt from the AREDS formula.
Therefore it was only recommended to high-risk
patients (i.e. category 3 or 4). For low risk patients
(i.e. category 1 or 2), recommendation was deferred
until indicated [17].
Potential risks of the AREDS formula include
kidney stones from vitamin C; fatigue, muscle
weakness, decreased thyroid function, and increased
hemorrhagic stroke risk from vitamin E; increased
lung cancer risk in smokers and yellow discoloration
of skin from beta-carotene; and anemia, decreased
serum high-density lipoprotein cholesterol, and stom-
ach upset from zinc [18]. Despite numerous potential
side effects, the only documented statistically signif-
icant ones were increased genitourinary symptoms,
increased self-reported anemia, and yellow discolor-
ation of skin. Although there was an increase in self-
reported anemia, no signiﬁcant change in blood
hematocrit level was found. Smokers were discour-
aged from taking pills containing beta-carotene, so an
increased risk of lung cancer with beta-carotene was
not addressed in the AREDS, but it has already been
established in two other trials [19, 20]. Nevertheless,
the few side effects were minor and the formula was
otherwise considered safe. In any case, patients
should always be informed of the risks and when
signiﬁcant contraindications exist (smoking, vascular
diseases, hyperlipidemia, risk of hemorrhage, etc.),
they should be discouraged from taking the formula.
Instead of an active supplementation formula,
some have proposed an enriched diet alone. The
Rotterdam Study investigated the effect of a vitamin-
and mineral-rich diet alone in the prevention of AMD
[21]. In comparison to the AREDS, no active
interventions were given. Baseline dietary content
was assessed, and followed up for possible develop-
ment of AMD. The study found that an above-median
intake of vitamin C and E, beta-carotene, and zinc
was associated with a striking 35% decrease in
incident AMD [21]. They concluded that such a diet
should be recommended to those with early signs of
AMD or those with a strong family history.
A recent meta-analysis carried out by the Cochrane
Collaboration reviewed the evidence and concluded
that both these recommendations were sound but
patients should nevertheless be warned of potential
harmful effects, particularly those who smoke or who
have vascular diseases [22]. Since patients take these
pills on a prophylactic basis, it is undesirable to have
complications arising.
Lutein and zeaxanthin
Also of great interest is the antioxidant balance
among macular pigments, mainly lutein and its
stereo-isomer, zeaxanthin. These carotenoids exist
Table 2 Dosages of the Age-Related Eye Disease Study (AREDS) type formulas compared with common fruit items
Nutrient AREDS [17] DRI
a Orange
b Apple
b Blueberry
b Banana
b Mango
b Strawberry
b Watermelon
b
Vitamin A
c (IU) 5000 3000 225 54 22 64 765 18 569
Vitamin C (mg) 500 90 53.2 4.6 0.7 8.7 27.7 13.7 8.1
Vitamin E (mg) 400 15 0.1 0.18 0.23 0.10 1.12 0.1 0.05
Zinc (mg) 80 11 0.07 0.04 0.1 0.15 0.04 0.06 0.1
Copper (mg) 2 0.9 0.045 0.027 0.12 0.078 0.11 0.03 0.042
Lutein/zeaxanthin (lg) None No data 129 29 33 22 0 9 8
a Dietary Reference Intakes from the Institute of Medicine [16]
b Nutrient contents of common fruit items are measured per 100 g
c Vitamin A as beta-carotene
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123in high concentrations in the macula, hence its
yellowish color. In vitro studies have shown that
both protect the retina from oxidative stress [23].
These carotenoids act in biological systems as (1) an
important structural molecule in cell membranes, (2)
a short-wavelength light ﬁlter, (3) a keeper of the
redox balance, and (4) a modulator in signal trans-
duction pathways [24, 25]. However, the human body
is not capable of lutein synthesis; it can only be
obtained from diet. Hence, supplementing the body
with lutein may offer protection against AMD.
However, these were not included in the AREDS
because neither of the two substances was ready for
manufacturing as a research formula [18].
The Carotenoids in Age-Related Eye Disease
Study (CAREDS) followed 1,787 American women
aged 50–79 for 4–7 years [26]. Subjects were divided
according to their average intake of dietary lutein and
zeaxanthin, but here were no statistical differences
between the amount of lutein and zeaxanthin they
took and the risk of development of AMD.
Conversely, two other studies were in favor of the
hypothesis. The cohort Pathologies Oculaires Lie ´es a `
l’Age (POLA) measured actual plasma carotenoids
levels from 899 subjects and correlated them with
risk of AMD. A striking reduction in risk was found
in those with a high plasma level: the odds ratios
were 0.31 and 0.07 for lutein and zeaxanthin,
respectively [27]. This was in agreement with another
similar study in the UK, where a high plasma
zeaxanthin was associated with a 50% reduction in
risk of AMD [28].
The US Food and Drug Administration (FDA)
denied a link between the carotenoids and AMD
protection after reviewing some interventional and
observational randomized studies [29]. In view of the
contradicting results, the National Eye Institute
(Bethesda, Maryland, USA) launched the Age-
Related Eye Disease Study 2 (AREDS2) in autumn
of 2006, hoping to answer this question. As well as
carotenoids, it also studies omega-3 [30, 31]. It also
modiﬁes the original formula by eliminating beta-
carotene, which increases the risk of lung cancer in
smokers. The proposed study end time is late 2012. In
the meantime, no evidence-based conclusion can be
reached.
Although not yet proven for beneﬁts, many
manufacturers have been including lutein and zea-
xanthin in their supplements, many of which are
available over the counter. In 2006, the Council for
Responsible Nutrition (CRN) in Washington DC
reviewed the risk proﬁle of lutein and concluded that
the only documented side effect is yellow discolor-
ation of skin, characterized by high dermal carotei-
noid levels. This condition is reversible and benign
and there were no other adverse events [32]. The
CRN also suggested a daily lutein upper level of
supplementation (ULS) of 20 mg. Lutein and zea-
xanthin carry potential beneﬁts, and have minimal
side effects. For those who are keen and are at risk of
AMD, they may offer some protection.
Omega-3 fatty acids
The role of omega-3 fatty acids in reducing the
incidence of cardiovascular diseases and strokes has
been well established [33]. For instance, the Amer-
ican Heart Association recommends the intake of
omega-3 fatty acids in the form of either ﬁsh or ﬁsh
oil capsule supplements for cardiovascular beneﬁts
[34]. Recently, its role in AMD has also been
investigated. Docosahexaenoic acid (DHA) is a type
of omega-3 fatty acid present in high concentration in
the photoreceptor segment of the retina. It is
constantly being shed and reformed in the normal
visual cycle, and has been shown to reduce inﬂam-
mation and regulate autoimmune responses [35–40],
which in turn prevents AMD. Hodge et al. carried out
a meta-analysis and concluded that evidence so far
was inconsistent and not randomized [41]. Larger
randomized controlled trials are needed before con-
clusions can be drawn.
More recently, the US Twin Study of Age-Related
Macular Degeneration (USTS) investigated the rela-
tionship among 681 twins, and found that ﬁsh
consumption and omega-3 fatty acid intake reduced
the risk of AMD [42], by an estimated 22% if omega-
3 was high. However, the study was not randomized
and hence its impact is limited.
Because of the potential antithrombotic effect of
ﬁsh oil, the risk of hemorrhagic stroke is potentially
increased [43]. Clinical studies have demonstrated
that even with concurrent administration of agents
like warfarin and aspirin, a high dose of ﬁsh oil does
not signiﬁcantly increase the risk of bleeding
[44–46]. Another safety concern is environmental
contaminants such as mercury, which is commonly
76 Int Ophthalmol (2011) 31:73–82
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capsules may pose potential health threats. The FDA
issued an advisory statement recommending that
pregnant women, breast-feeding mothers and children
avoid eating certain types of seafood high in mercury
[47]. The risk is still low and is limited to certain
types of ﬁsh such as golden bass, shark, king
mackerel, and swordﬁsh [33]. Fish oil supplements
are generally considered safe because most industrial
puriﬁcation processes eliminate these toxins [48, 49].
The risk of taking omega-3 fatty acids either from
dietary ﬁsh or ﬁsh oil supplements is low, and the
potential beneﬁts outweigh the risks. With the proven
cardiovascular beneﬁts, consumption of ﬁsh or ﬁsh
oil supplements remains a reasonable and safe
recommendation.
Berry extracts
The interest in berry extracts grew from their anti-
oxidant properties. Probably the most notable mem-
ber of the berry family is blueberry, which ranked
ﬁrst in antioxidant properties among 100 common
food items published by the United States Depart-
ment of Agriculture assays [50]. As far as ophthal-
mology is concerned, its antioxidant strength helps
reduce risk of AMD, and improves night vision.
Many berry extract products claim to protect eyes
from AMD. Another berry, wolfberry, better known
as ‘goji berry’, which has been long used in
Traditional Chinese Medicine (TCM), is also known
for its eye-protecting properties [51].
Anthocyanin is commonly present, and in plant
studies it was found to absorb blue-green light and
protect cells from light stress [52]. Other laboratory
studies have shown that it can theoretically protect
eyes from degenerative diseases like AMD [53–55].
Others also suggested anti-angiogenic and anti-cancer
properties in anthocyanin [53, 56, 57]. However, at
the moment evidence is limited to the laboratory
level. The precise dosage and frequency remains
uncertain, and potential toxicity and long-term side
effects still require exploration.
Currently there are no legal requirements for
quality control of these extracts. Most of these
products need not disclose their exact content and
production method. At the moment, berry extracts
should not be recommended.
Lifestyle modiﬁcations
Smoking cessation
The only established causative factor for AMD is
smoking, which has been linked to increased oxida-
tive stress, platelet aggregation, higher ﬁbrinogen
level, and reduced plasma high-density lipoprotein
and antioxidant levels [58–60].
In AREDS Report No. 19, subjects who smoke
were found to have a higher risk of progression to
advanced AMD. For 10 pack-years or higher smok-
ers, the odds ratio for advanced AMD was 1.55 [61].
Results of the US Twin Study showed that current
smokers had a 1.9-fold increased risk of having
AMD, and ex-smokers still had a 1.7-fold increased
risk [42]. If smokers take supplements containing
beta-carotene, the risk of lung cancer is further
increased [19, 20]. All smokers should be advised to
stop.
Body mass index (BMI)
In the AREDS, a higher risk of the geographical
atrophy type of AMD was seen in subjects with
higher BMI [19, 20, 61]. The odds ratio was 1.93 in
obese individuals (obese BMI C 30 kg/m [2], normal
BMI 18.5–24.9 kg/m [2]). Another study by Seddon
et al. also produced similar results [62].
Reducing light exposure
Sunglasses
Some studies have suggested that sunlight exposure
may contribute to AMD [63–73]. The Beaver Dam
Eye Study (BDES) was a population-based cohort
study measuring the amount of sunlight exposure and
incidence of AMD in 2,764 subjects over a 10-year
period [74]. The BDES found that extended sunlight
exposure was associated with higher incidence of
early AMD. However, the protective effect of
sunglasses was only marginal, and the data were
reported on a subjective basis.
More supporting evidence comes from reports on
the incidence of AMD after cataract surgery and
intraocular lens (IOL) implantation [75–77]. Human
crystalline lens turns yellow with age and has been
proven to protect the retina from harmful ultraviolet
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the crystalline lens is removed during surgery, the
implanted IOL does not provide equivalent theoret-
ical protection in vivo [79]. For those who have had
cataract surgery, wearing sunglasses in outdoor areas
may provide protection in this regard.
Spectral ﬁltering IOLs
A theoretical link has been proposed between photo-
toxicity and cataract extraction [80]. Most modern-
day IOLs mimic the crystalline lens in ﬁltering the
harmful UV spectrum of 300–400 nm [78, 81]. The
human crystalline lens turns yellow with age, thereby
blocking blue light (400–500 nm), while IOLs tend to
be transparent [82].
In the Chesapeake Bay Watermen Study, a signif-
icant correlation between blue or visible light expo-
sure and AMD was found [68]. In fact, after cataract
extraction, blue light exposure is greater than at any
other point in life [83].
Among the blue-light blocking properties of modern
IOLs (better known as ‘Yellow IOLs’), transmittance
mimics that of a human adult crystalline lens. One
example is the AcrySof
 Natural IOL by Alcon (Fort
Worth, Texas, USA), which partially attenuates violet
light (400–440 nm) [84], and blocks 50% of blue light
at 450 nm and 25% at 480 nm [85]. In contrast,
conventional transparent IOLs transmit 90% of light
[400 nm [82]. Therefore these yellow IOLs may
theoretically protect the macula from phototoxicity.
Concerns have been raised that these yellow IOLs
attenuate visual performances under scotopic condi-
tions (deﬁned as lighting levels as experienced on a
moonless night with only starlight), because blue
light, which is more informative in this environment,
is being partially ﬁltered [82]. Furthermore, some
raised the issue of possible differences in color
perception. For instance, driving at night is consid-
ered a mesopic task [86], which refers to lighting
conditions under a quarter of a full moon [87]. Even
under scotopic conditions, contrast sensitivity is
greatest around the 507 nm wavelength, and the
AcrySof Natural IOL transmits 85% of light at this
wavelength, as compared to 90% with conventional
transparent IOLs, and only around 60% in a young
Table 3 Summary of recommendations
Category Study Recommendation Strength of
evidence
a
Rating of
recommendation
a
Nutritional supplements
AREDS formula AREDS Regular intake may reduce risk of neovascular AMD I B
Cochrane [22] Regular intake may reduce risk of neovascular AMD I A
Lutein and zeaxanthin AREDS2 Not yet available n/a n/a
CAREDS No difference II C
POLA Higher lutein and zeaxanthin reduced risk of AMD II C
Gale et al. [28] Higher lutein and zeaxanthin reduced risk of AMD II C
Omega-3 AREDS2 Not yet available n/a n/a
USTS Higher omega-3 intake reduced risk of AMD II C
Berry extracts None n/a n/a n/a
Life style
Smoking AREDS Smokers had higher risk of AMD I B
USTS Smokers had higher risk of AMD II C
BMI AREDS Higher BMI was associated with higher risk of AMD I B
Sunlight ﬁltering
Sunglasses BDES Beneﬁt of sunglasses use against AMD marginal II C
Yellow IOLs None n/a n/a n/a
n/a data not available, AREDS Age-Related Eye Disease Study [17], AREDS2 Age-Related Eye Disease Study 2 [31], CAREDS
Carotenoids in Age-Related Eye Disease Study [26], POLA ‘Pathologies Oculaires Lie ´es a ` l’Age’ study [27], USTS United States
Twins Study [42], BDES Beaver Dam Eye Study [66]
a Strength of evidence and rating of recommendation rated according to method described previously [9]
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studies even reported increased contrast sensitivity
with the yellow IOLs [88–90].
Cionni used the Farnsworth 100-Hue test in
subjects who had undergone bilateral yellow IOL
implantation, and found no signiﬁcant changes in
terms of color perception [91]. Comparison was also
made with those who had a yellow IOL implanted in
one eye, and a transparent IOL in the other, and found
no signiﬁcant alternations [92]. Hence for most
patients a yellow IOL may offer theoretical protec-
tion from AMD.
Summary and conclusions
A systematic review of evidence on the prevention of
age-related macular degeneration was made. A
summary of recommendations is given in Table 3.
The AREDS formula remains the only A-rated
recommendation so far. When dealing with patients,
it is the responsibility of the practitioner to fully
explain the nature of supplements and potential side
effects from long-term regular intake, especially the
increased risk of lung cancer in smokers. Any
misconceptions should be addressed and rectiﬁed. It
is also necessary to remind patients that even when
taking the AREDS formula, AMD can still occur.
Patients should be taught self-monitoring methods
and undergo regular fundal examinations by qualiﬁed
ophthalmologists. The importance of this cannot be
over-emphasized.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction
in any medium, provided the original author(s) and source are
credited.
References
1. Eye Disease Prevalence Research Group (2004) Prevalence
of age-related macular degeneration in the United States.
Arch Ophthalmol 122:564–572
2. Evans J, Wormald R (1996) Is the incidence of registrable
age-related macular degeneration increasing? Br J Oph-
thalmol 80:9–14
3. VanNewkirk M, Weih LM, McCarty CA, Taylor HR
(2001) Cause-speciﬁc prevalence of bilateral visual
impairment in Victoria, Australia: the visual impairment
project. Ophthalmology 108:960–967
4. Bressler NM (2000) Age related macular degeneration.
New hope for a common problem comes from photody-
namic therapy. BMJ 321:1425–1427
5. Zarbin MA (2004) Current concepts in the pathogenesis of
age-related macular degeneration. Arch Ophthalmol 122:
598–614
6. Beatty S, Koh H, Phil M, Henson D, Boulton M (2000) The
role of oxidative stress in the pathogenesis of age-related
macular degeneration. Surv Ophthalmol 45:115–134
7. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Rani-
bizumab for neovascular age-related macular degeneration.
N Engl J Med 355:1419–1431
8. Gupta OP, Brown GC, Brown MM (2007) Age-related
macular degeneration: the costs to society and the patient.
Curr Opin Ophthalmol 18:201–205
9. Minckler D (2000) Evidence-based ophthalmology series
and content-based continuing medical education for the
journal. Ophthalmology 107:9–10
10. Seddon JM, Ajani UA, Sperduto RD, Eye Disease Case-
Control Study Group et al (1994) Dietary carotenoids,
vitamins A, C, and E, and advanced age-related macular
degeneration. JAMA 272:1413–1420
11. Snellen EL, Verbeek AL, Van Den Hoogen GW,
Cruysberg JR, Hoyng CB (2002) Neovascular age-related
macular degeneration and its relationship to antioxidant
intake. Acta Ophthalmol Scand 80:368–371
12. Goldberg J, Flowerdew G, Smith E, Brody JA, Tso MO
(1988) Factors associated with age-related macular
degeneration: an analysis of data from the ﬁrst National
Health and Nutrition Examination Survey. Am J Epidemiol
128:700–710
13. VandenLangenberg GM, Mares-Perlman JA, Klein R,
Klein BE, Brady WE, Palta M (1998) Associations
between antioxidant and zinc intake and the 5-year inci-
dence of early age-related maculopathy in the Beaver Dam
Eye Study. Am J Epidemiol 148:204–214
14. Newsome DA, Swartz M, Leone MC, Elston RC, Miller E
(1988) Oral zinc in macular degeneration. Arch Ophthal-
mol 106:192–198
15. Moriarty-Craige SE, Ha K-N et al (2007) Effects of long-
term zinc supplementation on plasma thiol metabolites and
redox status in patients with age-related macular degen-
eration. Am J Ophthalmol 143:206–211
16. Dietary Reference Intakes, Institute of Medicine of the
National Academies website. http://www.iom.edu/CMS/
3788/4574.aspx. Accessed 15 December 2007
17. The Age-Related Eye Disease Study Research Group
(2001) A randomized, placebo-controlled, clinical trial of
high-dose supplementation with vitamins C and E, beta
carotene, and zinc for age-related macular degeneration
and vision loss. AREDS Report No. 8. Arch Ophthalmol
119:1417–1436
18. Klein R, Peto T, Bird A et al (2004) The epidemiology of
age-related macular degeneration. Am J Ophthalmol
137:486–495
19. Omenn GS, Goodman GE, Thornquist MD et al (1996)
Effects of a combination of beta carotene and vitamin A on
lung cancer and cardiovascular disease. N Engl J Med
334:1150–1155
20. The Alpha-Tocopherol Beta Carotene Cancer Prevention
Study Group (1994) The effect of vitamin E and beta
Int Ophthalmol (2011) 31:73–82 79
123carotene on the incidence of lung cancer and other cancers
in male smokers. N Engl J Med 330:1029–1035
21. van Leeuwen R, Boekhoorn S, Vingerling JR, Witteman
JC, Klaver CC, Hofman A, de Jong PT (2005) Dietary
intake of antioxidants and risk of age-related macular
degeneration. JAMA 294:3101–3107
22. Evans JR (2006) Antioxidant vitamin and mineral sup-
plements for slowing the progression of age related mac-
ular degeneration. Cochrane Database Syst Rev (2):CD000
254
23. Sujak A, Gabrielska J, Grudzinski W, Borc R et al (1999)
Lutein and zeaxanthin as protectors of lipid membranes
against oxidative damage: the structural aspects. Arch
Biochem Biophys 371:301–307
24. Rosenthal JM, Kim J, Monastario F et al (2006) Dose-
ranging study of lutein supplementation in persons aged
60 years or older. Invest Ophthalmol Vis Sci 47:5227–5233
25. Whitehead AJ, Mares JA, Danis RP (2006) Macular pig-
ment: a review of current knowledge. Arch Ophthalmol
124:1038–1045
26. Moeller SM, Parekh N, Tinker L, CAREDS Research
Study Group et al (2006) Associations between interme-
diate age-related macular degeneration and lutein and
zeaxanthin in the Carotenoids in Age-Related Eye Disease
Study (CAREDS): ancillary study of the Women’s Health
Initiative. Arch Ophthalmol 124:1151–1162
27. Delcourt C, Carrie `re I, Delage M, Barberger-Gateau P,
Schalch W, the POLA Study Group (2006) Plasma lutein
and zeaxanthin and other carotenoids as modiﬁable risk
factors for age-related maculopathy and cataract: the
POLA study. Invest Ophthalmol Vis Sci 47:2329–2335
28. Gale CR, Hall NF, Phillips DI, Martyn CN (2003) Lutein
and zeaxanthin status and risk of age-related macular
degeneration. Invest Ophthalmol Vis Sci 44:2461–2465
29. Trumbo PR, Ellwood KC (2006) Lutein and zeaxanthin
intakes and risk of age-related macular degeneration and
cataracts: an evaluation using the Food and Drug Admin-
istration’s evidence-based review system for health claims.
Am J Clin Nutr 84:971–974
30. Coleman H, Chew E (2007) Nutritional supplementation in
age-related macular degeneration. Curr Opinion Ophthal-
mol 18:220–223
31. AREDS2 website. http://www.nei.nih.gov/neitrials/view
StudyWeb.aspx?id=120. Accessed 15 December 2009
32. Shao A, Hathcock JN (2006) Risk assessment for the
carotenoids lutein and lycopene. Regul Toxicol Pharmacol
45:289–298
33. Mozaffarian D, Rimm EB (2006) Fish intake, contami-
nants, and human health: evaluating the risks and the
beneﬁts. JAMA 296:1885–1899
34. Bang HO, Dyerberg J (1980) Lipid metabolism and
ischaemic heart disease in Greenland Eskimos. In: Draper
H (ed) Advances in nutrition research. Plenum Press, New
York, pp 1–22
35. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N
(2004) Association between C-reactive protein and age-
related macular degeneration. JAMA 291:704–710
36. Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C,
Farrer LA (2005) Complement factor H polymorphism and
age-related macular degeneration. Science 308:421–424
37. Klein RJ, Zeiss C, Chew E et al (2005) Complement factor
H polymorphism in age-related macular degeneration.
Science 308:385–389
38. Hageman GS, Anderson DH, Johnson LV et al (2005) A
common haplotype in the complement regulatory gene
factor H (HF1/CFH) predisposes individuals to age-related
macular degeneration. Proc Natl Acad Sci USA
102:7227–7232
39. Haines JL, Hauser MA, Schmidt S et al (2005) Comple-
ment factor H variant increases the risk of age-related
macular degeneration. Science 308:419–421
40. Horrocks LA, Yeo YK (1999) Health beneﬁts of docosa-
hexaenoic acid (DHA). Pharmacol Res 40:211–225
41. Hodge WG, Schachter HM, Barnes D et al (2006) Efﬁcacy
of x-3 fatty acids in preventing age-related macular
degeneration: a systematic review. Ophthalmology 113:
1165–1173
42. Seddon JM, George S, Rosner B (2006) Cigarette smoking,
ﬁsh consumption, omega-3 fatty acid intake, and associa-
tions with age-related macular degeneration: the US Twin
Study of age-related macular degeneration. Arch Oph-
thalmol 124:995–1001
43. Carroll DN, Roth MT (2002) Evidence for the cardiopro-
tective effects of omega-3 fatty acids. Ann Pharmacother
36:1950–1956
44. Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor
M (1996) Effect of dietary supplementation with n-3 fatty
acids on coronary artery bypass graft patency. Am J Car-
diol 77:31–36
45. Leaf A, Jorgensen MB, Jacobs AK et al (1994) Do ﬁsh oils
prevent restenosis after coronary angioplasty? Circulation
90:2248–2257
46. Bender NK, Kraynak MA, Chiquette E, Linn WD, Clark
GM, Bussey HI (1998) Effects of marine ﬁsh oils on the
anticoagulation status of patients receiving chronic war-
farin therapy. J Thromb Thrombolysis 5:257–261
47. US Department of Health and Human Services, US Envi-
ronmental Protection Agency. What you need to know
about mercury in ﬁsh and shellﬁsh. CFSAN Website.
Available at http://www.cfsan.fda.gov/dms/admehg3.html.
Accessed 15 December 2007
48. Foran SE, Flood JG, Lewandrowski KB (2003) Measure-
ment of mercury levels in concentrated over-the-counter
ﬁsh oil preparations: is ﬁsh oil healthier than ﬁsh? Arch
Pathol Lab Med 127:1603–1605
49. Good news! These supplements have omega-3’s without
contaminants found in ﬁsh! But some are better than oth-
ers. Find out now! [report.] ConsumerLab.com Website.
Available at http://www.consumerlab.com/results/omega3.
asp. Accessed 15 December 2007
50. Dietary Guidance, National Agricultural Library, United
States Department of Agriculture website. http://riley.nal.
usda.gov/nal_display/index.php?info_center=4&tax_level=2
&tax_subject=256&topic_id=1342. Accessed 15 December
2007
51. Wang X, Hu S (2001) A review of research actuality on
age-related macular degeneration. Yan Ke Xue Bao
17(4):245–251
52. Liakopoulos G et al (2006) The photoprotective role of
epidermal anthocyanins and surface pubescence in young
80 Int Ophthalmol (2011) 31:73–82
123leaves of grapevine (Vitis vinifera). Ann Bot (Lond)
98(1):257–265
53. Bagchi D, Sen CK, Bagchi M, Atalay M (2004) Anti-
angiogenic, antioxidant, and anti-carcinogenic properties
of a novel anthocyanin-rich berry extract formula. Bio-
chemistry (Mosc) 69(1):75–80; 1 p preceding 75. Review
54. Sadilova E, Carle R, Stintzing FC (2007) Thermal degra-
dation of anthocyanins and its impact on color and in vitro
antioxidant capacity. Mol Nutr Food Res 51(12):1461–
1471
55. Bagchi D, Roy S, Patel V et al (2006) Safety and whole-
body antioxidant potential of a novel anthocyanin-rich
formulation of edible berries. Mol Cell Biochem
281(1–2):197–209
56. Faria A, Oliveira J, Neves P, Gameiro P, Santos-Buelga C,
de Freitas V, Mateus N (2005) Antioxidant properties of
prepared blueberry (Vaccinium myrtillus) extracts. J Agric
Food Chem 53(17):6896–6902
57. Lamy S, Blanchette M, Michaud-Levesque J, Laﬂeur R,
Durocher Y, Moghrabi A, Barrette S, Gingras D, Beliveau
R (2006) Delphinidin, a dietary anthocyanidin, inhibits
vascular endothelial growth factor receptor-2 phosphory-
lation. Carcinogenesis 27(5):989–996; Epub 2005 Nov 23
58. Roy S, Khanna S, Alessio HM, Vider J, Bagchi D, Bagchi
M, Sen CK (2002) Anti-angiogenic property of edible
berries. Free Radic Res 36(9):1023–1031
59. Tomany SC, Wang JJ, van Leeuwen R et al (2004) Risk
factors for incident age-related macular degeneration:
pooled ﬁndings from 3 continents. Ophthalmology
111:1280–1287
60. The health consequences of smoking: a report of the sur-
geon general, 2005. http://www.cdc.gov/tobacco/sgr/sgr_
2004/index.htm. Accessed 15 December 2007
61. Age-Related Eye Disease Study Research Group (2005)
Risk factors for the incidence of advanced age-related
macular degeneration in the Age-Related Eye Disease
Study (AREDS): AREDS report No. 19. Ophthalmology
112:533–539
62. Seddon JM, Cote J, Davis N, Rosner B (2003) Progression
of age-related macular degeneration: association with body
mass index, waist circumference, and waist-hip ratio. Arch
Ophthalmol 121:785–792
63. Eye Disease Case-Control Study Group (1992) Risk factors
for neovascular age related macular degeneration. Arch
Ophthalmol 110:1701–1708
64. Age-Related Eye Disease Study Research Group (2000)
Risk factors associated with age-related macular degener-
ation. Ophthalmology 107:2224–2232
65. Klein R, Clegg L, Cooper LS et al (1999) Prevalence of
age-related maculopathy in the Atherosclerosis Risk in
Communities Study. Arch Ophthalmol 117:1203–1210
66. Klein R, Klein BEK, Tomany SC, Moss SE (2002) Ten-
year incidence of age-related maculopathy and smoking
and drinking: the Beaver Dam Eye Study. Am J Epidemiol
156:589–598
67. West SK, Rosenthal FS, Bressler NM et al (1989) Expo-
sure to sunlight and other risk factors for age-related
macular degeneration. Arch Ophthalmol 107:875–879
68. Taylor HR, West SK, Munoz MS et al (1992) The long-
term effect of visual light to the eye. Arch Ophthalmol
110:99–104
69. Cruickshanks KJ, Klein R, Klein BEK (1993) Sunlight and
age-related macular degeneration: the Beaver Dam Eye
Study. Arch Ophthalmol 111:514–518
70. Cruickshanks KJ, Klein R, Klein BEK, Nondahl DM
(2001) Sunlight and the 5-year incidence of early age-
related maculopathy: the Beaver Dam Eye Study. Arch
Ophthalmol 119:246–250
71. Darzins P, Mitchell P, Heller RF (1997) Sun exposure and
age-related macular degeneration: an Australian case-
control study. Ophthalmology 104:770–776
72. Mitchell P, Smith W, Wang JJ (1998) Iris color, skin sun
sensitivity, and age-related maculopathy: the Blue Moun-
tains Eye Study. Ophthalmology 105:1359–1363
73. Delcourt C, Carriere I, Ponton-Sanchez A et al (2001)
Light exposure and the risk of age-related macular
degeneration. Arch Ophthalmol 119:1463–1468
74. Tomany SC, Cruickshanks KJ, Klein R et al (2004) The
Beaver Dam Eye Study: sunlight and the 10-year incidence
of age-related maculopathy. Arch Ophthalmol 122:750–
757
75. Klein R, Klein BE, Wong TY et al (2002) The association
of cataract and cataract surgery with the long-term inci-
dence of age-related maculopathy: the Beaver Dam eye
study. Arch Ophthalmol 120:1551–1558
76. Wang JJ, Klein R, Smith W et al (2003) Cataract surgery
and the 5-year incidence of late-stage age-related macu-
lopathy: pooled ﬁndings from the Beaver Dam and Blue
Mountains eye studies. Ophthalmology 110:1960–1967
77. Freeman EE, Munoz B, West SK et al (2003) Is there an
association between cataract surgery and age-related
macular degeneration? Data from three population-based
studies. Am J Ophthalmol 135:849–856
78. Boettner EA, Wolter JR (1962) Transmission of the ocular
media. Invest Ophthalmol 1:776–783
79. Mainster MA (2006) Violet and blue light blocking intra-
ocular lenses: photoprotection versus photoreception. Br J
Ophthalmol 90:784–792
80. Cugati S, Mitchell P, Rochtchina E et al (2006) Cataract
surgery and the 10-year incidence of age-related macu-
lopathy: The Blue Mountain Eye Study. Ophthalmology
113:2020–2025
81. Mainster MA (1986) The spectra, classiﬁcation, and
rationale of ultraviolet-protective intraocular lenses. Am J
Ophthalmol 102:727–732
82. Braunstein RE, Sparrow JR (2005) A blue-blocking intra-
ocular lens should be used in cataract surgery. Arch Oph-
thalmol 123:547–549
83. Pollack A, Marcovich A, Bukelman A et al (1996) Age-
related macular degeneration after extracapsular cataract
extraction with intraocular lens implantation. Ophthal-
mology 103:1546–1554
84. Sparrow J, Miller AS, Zhou J (2004) Blue light absorbing
intraocular lens and retinal pigment epithelium protection
in vivo. J Cat Refract Surg 30:873–878
85. Alcon Laboratories 1 (2003) AcrySof Natural Single-Piece
IOL Product Monograph. Alcon Laboratories 1, Fort
Worth
86. Mainster MA, Timberlake GT (2003) Why HID headlights
bother older drivers. Br J Ophthalmol 87:113–117
87. Marshall J, Greenstein V, Kline D, Owsley C, Werner JS
(1986) Optical radiation and the aged eye. In: Waxler M,
Int Ophthalmol (2011) 31:73–82 81
123Hitchins VM (eds) Optical radiation and visual health.
CRC Press, Boca Raton, pp 43–67
88. de Fez MD, Luque MJ, Viqueira V (2002) Enhancement of
contrast sensitivity and losses of chromatic discrimination
with tinted lenses. Optom Vis Sci 79:590–597
89. Wolffsohn JS, Cochrane AL, Khoo H, Yoshimitsu Y, Wu S
(2000) Contrast is enhanced by yellow lenses because of
selective reduction of short-wavelength light. Optom Vis
Sci 77:73–81
90. Rabin J, Wiley R (1996) Differences in apparent contrast
in yellow and white light. Ophthalmic Physiol Opt 16:68–
72
91. Cionni RJ (2004) Color perception in patients with UV or
blue-light-ﬁltering IOLs. In: Symposium on cataract, IOL
and refractive surgery. American Society of Cataract and
Refractive Surgery, San Diego. Abstract 337
92. Tjia K (2004) AcrySof Natural SN60 and clear SA60 IOLs:
intraindividual comparison. In: Symposium on cataract,
IOL and refractive surgery. American Society of Cataract
and Refractive Surgery, San Diego. Abstract 426
82 Int Ophthalmol (2011) 31:73–82
123